A carregar...
CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
The survival of patients with multiple myeloma (MM) has been dramatically improved in the last decade thanks to the incorporation of second-generation proteasome inhibitors (PI), immunomodulatory drugs (IMID), and, more recently, anti-CD38 monoclonal antibodies (MoAb). Nevertheless, still, a major p...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7694626/ https://ncbi.nlm.nih.gov/pubmed/33172026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9113577 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|